Pharmaceutical Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

The gene-silencing approach to cutting cholesterol

The Medicine Company’s inclisiran, which is moving into phase III clinical trials, could halve cholesterol in patients at high risk of cardiovascular disease. Unlike all previous treatments, it works by ‘switching off’ one of the genes responsible for high cholesterol levels. Abi Millar profiles this new approach to tackling one of the world’s most persistent public health issues.

Go Top